¼¼°èÀÇ MRSA °Ë»ç ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 45¾ï ´Þ·¯, 2024³â 46¾ï 8,000¸¸ ´Þ·¯¿¡¼ 2032³â¿¡´Â 64¾ï 6,000¸¸ ´Þ·¯·Î ¼ºÀåÇϰí, ¿¹Ãø ±â°£(2025-2032³â) CAGRÀº 4.1%¸¦ º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.
¼¼°è MRSA °Ë»ç ½ÃÀåÀº Ç×»ýÁ¦ ³»¼º °¨¿°ÀÇ ½Å¼ÓÇÑ °ËÃâ¿¡ ´ëÇÑ ÀÇ·á ½Ã½ºÅÛÀÇ ±ä±ÞÇÑ ¿ä±¸·Î ÀÎÇØ ±Þ°ÝÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ¸ÞƼ½Ç¸° ³»¼º Ȳ»öÆ÷µµ»ó±¸±Õ(MRSA)Àº ƯÈ÷ º´¿ø ȯ°æ¿¡¼ ¿©ÀüÈ÷ °øÁߺ¸°Ç¿¡ Å« À§ÇùÀÌ µÇ°í ÀÖÀ¸¸ç, MRSA °¨¿°ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Á¤È®ÇÏ°í ½Å¼ÓÇÑ Áø´Ü °Ë»ç¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ´Ù¾çÇÑ ÀÇ·á ½Ã¼³¿¡¼ °¨¿° ¿¹¹æ¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖÀ¸¸ç, ¹ßº´À» ¾ïÁ¦Çϱâ À§ÇÑ ÇöÀå Áø·á ±â¼ú ¹× ºÐÀÚÁø´Ü ±â¼úÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÏ¸é¼ ½ÃÀå È®´ëÀÇ ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÚµ¿È Ç÷§Æû°ú PCR ±â¹Ý ºÐ¼®ÀÇ ¹ßÀüÀ¸·Î °ËÃâ ´É·ÂÀÌ Çâ»óµÇ°í ÀÓ»ó °á°ú°¡ °³¼±µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼±º°°Ë»ç °¡À̵å¶óÀÎÀÇ Àǹ«È¿Í Ç×±ÕÁ¦ ³»¼º¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó Áø´Ü¾÷üµéÀÌ ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇÔÀ¸·Î½á MRSA °Ë»ç°¡ Àü ¼¼°è °¨¿° °ü¸® Àü·«¿¡ ´õ¿í ³Î¸® º¸±ÞµÇ°í ÀÖ½À´Ï´Ù.
Global MRSA Testing Market size was valued at USD 4.5 billion in 2023 and is poised to grow from USD 4.68 billion in 2024 to USD 6.46 billion by 2032, growing at a CAGR of 4.1% during the forecast period (2025-2032).
The global MRSA testing market is witnessing significant growth, driven by healthcare systems' urgent need for rapid detection of antibiotic-resistant infections. Methicillin-resistant Staphylococcus aureus (MRSA) remains a major public health concern, particularly in hospital settings. As the prevalence of MRSA infections rises, so does the demand for accurate and timely diagnostic tests. The focus on infection control in various healthcare facilities is a key factor fueling market expansion, along with the increasing adoption of point-of-care and molecular diagnostic technologies aimed at curbing outbreaks. Advancements in automated platforms and PCR-based assays are enhancing detection capabilities, thus improving clinical outcomes. Additionally, mandatory screening guidelines and heightened awareness of antimicrobial resistance are pushing diagnostic companies to offer cost-effective solutions, further embedding MRSA testing into global infection control strategies.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global MRSA Testing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global MRSA Testing Market Segments Analysis
Global MRSA Testing Market is segmented by Product Type, Test Type, End user and region. Based on Product Type, the market is segmented into Instruments and Reagents & Kits. Based on Test Type, the market is segmented into Immunodiagnostic Test and Molecular Diagnostic Test. Based on End user, the market is segmented into Hospitals, Diagnostic Laboratories and Academic and Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global MRSA Testing Market
The increasing prevalence of antibiotic-resistant bacteria, particularly MRSA and VRSA, is driving a surge in hospital-acquired infections, notably in high-risk environments like intensive care units and dialysis facilities. Contributing factors include prolonged hospitalizations and the use of invasive medical procedures. This alarming trend underscores the urgent necessity for enhanced infection control strategies, as evidenced by concerning rates of MRSA colonization documented by health organizations such as the CDC and NHS. Consequently, the global MRSA testing market is expanding to address these critical healthcare challenges and improve patient outcomes through more effective diagnostic and treatment options.
Restraints in the Global MRSA Testing Market
The Global MRSA Testing market faces challenges primarily related to patient safety, particularly for vulnerable populations that rely heavily on healthcare services. The transmission of MRSA primarily occurs through direct contact and the use of medical devices. Additionally, contamination issues extend beyond traditional healthcare settings, impacting industries such as telecommunications and electronics, especially during the surface mount technology (SMT) and printed circuit board (PCB) assembly processes. This highlights a pressing need for effective infection prevention measures across various sectors, emphasizing that MRSA concerns are not limited to healthcare environments alone. Addressing these challenges is crucial for overall safety and risk management.
Market Trends of the Global MRSA Testing Market
The Global MRSA Testing market is experiencing a significant trend towards the adoption of AI-powered diagnostic platforms, transforming traditional testing methodologies. These innovative tools enhance diagnostic workflows by automating result interpretation, expediting image analysis, and improving detection accuracy, ultimately fostering better patient outcomes. With the implementation of AI, laboratories can achieve quicker turnaround times and heightened operational efficiency, which is crucial in high-risk healthcare environments. This technological advancement not only streamlines the testing process but also empowers healthcare professionals to implement timely infection control interventions, reflecting a paradigm shift in MRSA management and detection strategies worldwide.